Evaluation of the effect of AngiotensinII receptor blocker on coronary artery after Sirolimus-Eluting Stent implantatio
Not Applicable
- Conditions
- Hypertension with coronary artery disease
- Registration Number
- JPRN-UMIN000001822
- Lead Sponsor
- Toyohashi Heart Ceter, Cardiovascular Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
"1) Patients with coronary vasospasm 2) Patients who have lesions that are applicable to exclusion criteria 3) Previous cerebrovascular event <= 6month 4) Severe gastrointestinal bleeding <= 3month 5) Patients who contraindicate antithronbotic and anticoagulant therapy 6) Patients who have severe allergy to contrast dye 7) Ejection fraction <= 30%"
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie ARB effects on coronary artery healing after Sirolimus-Eluting Stent implantation in JPRN-UMIN000001822?
How does ARB therapy compare to standard-of-care treatments for preventing restenosis in hypertensive coronary artery disease patients post-SES implantation?
Which biomarkers correlate with improved vascular outcomes in JPRN-UMIN000001822 ARB-treated patients with hypertension and CAD?
What adverse events are associated with ARB use in JPRN-UMIN000001822 and how do they compare to other post-stent therapies?
Are there synergistic effects of combining ARBs with other antihypertensive agents in managing neointimal hyperplasia after SES implantation?